Novel hybrid liposomal formulations based on imidazolium-containing amphiphiles for drug encapsulation.
Novel liposomes based on 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and imidazolium-containing amphiphiles with various length of hydrophobic tail at various molar ratio of components have been fabricated. Obtained formulations were characterized using dynamic and electrophoretic light scattering as well as transmission electron microscopy techniques. It has been established, that DPPC liposomes modification by these cationic amphiphiles resulted in zeta potential increase from +3 mV to +45-70 mV and improve its stability for a long time (more than 6 months, whereas unmodified liposomes have been destructed after 2 weeks of storage). Hydrodynamic diameter of prepared hybrid liposomes was in the range of 70-100 nm depending on its composition. Fabricated hybrid carriers have been used for drug (metronidazole) encapsulation. It has been shown, that superior encapsulation characteristics (encapsulation efficiency was 75%) exhibited hybrid liposomes composed from octadecyl derivative. Increase of the time of total release of encapsulated drug from hybrid liposomes in comparison with unencapsulated drug by 1.7 times has been demonstrated.